Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymalfasin Combined With Chemotherapy and Immunotherapy for Neoadjuvant Treatment of Triple-Negative Breast Cancer
NCT07884201Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Nov 2026
- Primary completion
- Nov 2029
01
Overview
A Phase 2 trial of thymosin alpha 1 in triple-negative breast cancer (TNBC), sponsored by Fudan University. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
thymosin alpha 1
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07884201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07884201.